Growth Hormone, Glutamine, and an Optimal Diet Reduces Parenteral Nutrition in Patients With Short Bowel Syndrome

Byrne, Theresa A.; Wilmore, Douglas W.; Iyer, Kishore; DiBaise, John K.; Clancy, Kerri A.; Robinson, Malcolm K.; Chang, Peter; Gertner, Joseph M.; Lautz, David B.

doi:10.1097/01.sla.0000186479.53295.14

Cited by 194 publications

(103 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Short bowel syndrome is an intestinal disease characterized by malabsorption due to the surgical removal of up to 70 % of the small intestine (Byrne et al 2005). SBS symptoms include diarrhea, weight loss, fluid depletion, malnutrition and finally patient mortality.…”

Section: Short Bowel Syndrome (Sbs)mentioning

confidence: 99%

Intestinal stem cells and stem cell-based therapy for intestinal diseases

2014

View full text Add to dashboard Cite

Currently, many gastrointestinal diseases are a major reason for the increased mortality rate of children and adults every year. Additionally, these patients may cope with the high cost of the parenteral nutrition (PN), which aids in the long-term survival of the patients. Other treatment options include surgical lengthening, which is not sufficient in many cases, and intestinal transplantation. However, intestinal transplantation is still accompanied by many challenges, including immune rejection and donor availability, which may limit the transplant's success. The development of more safe and promising alternative treatments for intestinal diseases is still ongoing. Stem cell-based therapy (SCT) and tissue engineering (TE) appear to be the next promising choices for the regeneration of the damaged intestine. However, suitable stem cell source is required for the SCT and TE process. Thus, in this review we discuss how intestinal stem cells (ISCs) are a promising cell source for small intestine diseases. We will also discuss the different markers were used to identify ISCs. Moreover, we discuss the dominant Wnt signaling pathway in the ISC niche and its involvement in some intestinal diseases. Additionally, we discuss ISC culture and expansion, which are critical to providing enough cells for SCT and TE. Finally, we conclude and recommend that ISC isolation, culture and expansion should be considered when SCT is a treatment option for intestinal disorders. Therefore, we believe that ISCs should be considered a cell source for SCT for many gastrointestinal diseases and should be highlighted in future clinical applications.

show abstract

Section: Short Bowel Syndrome (Sbs)mentioning

confidence: 99%

Intestinal stem cells and stem cell-based therapy for intestinal diseases

2014

View full text Add to dashboard Cite

show abstract

“…Wyniki badań dotyczące pozajelitowego żywienia z glutaminą u chorych z ZKL są także niejednoznaczne [41,45,46]. U 15 chorych z ZKJ pozajelitowe podanie glutaminy (0,16 g/kg/dobę) z podskórnymi wstrzyknię-ciami hormonu wzrostu (0,03-0,14 mg/kg/dobę) powodowało poprawę absorpcji protein, obniżenie ilości wydalanego stolca i aż u 40% badanych zmniejszało potrzebę stosowania żywienia pozajelitowego [41].…”

Section: Zespół Krótkiego Jelitaunclassified

“…U chorych z ZKJ żywionych pozajelitowo Byrne i wsp. [46] stosowali suplementację glutaminą (dojelitowo 30 g/dobę) bez hormonu wzrostu i z hormonem wzrostu. W badanych grupach, w których podawany był hormon wzrostu, stwierdzono możliwość odstąpienia od żywienia pozajelitowego.…”

Section: Zespół Krótkiego Jelitaunclassified

“…W badanych grupach, w których podawany był hormon wzrostu, stwierdzono możliwość odstąpienia od żywienia pozajelitowego. Efekt ten utrzymywał się przez okres 3 miesięcy jedynie w grupie chorych otrzymujących hormon wzrostu wraz z glutaminą [46]. Na podstawie przedstawionych badań można wnioskować o korzystnym działaniu glutaminy podawanej z hormonem wzrostu, jednak zdaniem ESPEN dane te są niewystarczające, aby zalecać stosowanie tego aminokwasu u chorych z ZKJ [35,36].…”

Section: Zespół Krótkiego Jelitaunclassified

See 1 more Smart Citation

Nutritional support with glutamine according to recommendations of the European Society for Clinical Nutrition and Metabolism (ESPEN)

Kędziora¹,

Słotwiński²,

Dąbrowska³

2010

View full text Add to dashboard Cite

StreszczenieW stanach stresu metabolicznego (np. urazy, zapalenia, oparzenia, choroby nowotworowe, kacheksja) glutamina wykorzystywana jest jako źródło energii w większych ilościach niż w stanie fizjologicznym i staje się związkiem warunkowo niezbędnym. Dlatego też w takich sytuacjach zalecana jest jej suplementacja. Europejskie Towarzystwo Żywienia Klinicznego i Metabolizmu (ESPEN) od 2005 r. przedstawia zalecenia żywieniowe dotyczące pozajelitowego lub dojelitowego stosowania glutaminy w poszczególnych jednostkach chorobowych i konkretnych sytuacjach klinicznych. Niniejsza praca ma na celu zebranie i uporządkowanie aktualnych zaleceń ESPEN dotyczących suplementacji tego aminokwasu zarówno w żywieniu enteralnym, jak i parenteralnym. AbstractIn conditions of metabolic stress (trauma, burns, cancer, cachexia) glutamine as a source of energy is used more than in the physiological state and becomes a conditionally essential amino acid. Because of this, glutamine should be supplemented in these conditions. The European Society for Clinical Nutrition and Metabolism (ESPEN) since 2005 has presented recommendations of glutamine's use in different diseases and clinical states. This article presents current recommendations of glutamine supplementation in both enteral and parenteral nutrition.

show abstract

“…Intestinal rehabilitation programs typically incorporate individualized modification of oral diet is a cornerstone of therapy, in addition to optimization of anti-diarrheal medications, particularly as use of PN is weaned (6,17). Dietary modifications typically involve smaller, more frequent feedings, use of oral rehydration solutions and soluble fiber, avoidance of simple sugars, oxalate, and, in some cases, lactose and modification of fat intake and consumption of specific foods based on individual tolerance (2,(6)(7)(8).…”

mentioning

confidence: 99%

Nutrient intake from habitual oral diet in patients with severe short bowel syndrome living in the southeastern United States

et al. 2008

View full text Add to dashboard Cite

show abstract

Growth Hormone, Glutamine, and an Optimal Diet Reduces Parenteral Nutrition in Patients With Short Bowel Syndrome

Abstract: Treatment with GH + diet or GH + Gln + diet initially permitted significantly more weaning from PN than Gln + diet. Only subjects receiving GH + Gln + diet maintained this effect for at least 3 months.

Cited by 194 publications

References 24 publications

Intestinal stem cells and stem cell-based therapy for intestinal diseases

Intestinal stem cells and stem cell-based therapy for intestinal diseases

Nutritional support with glutamine according to recommendations of the European Society for Clinical Nutrition and Metabolism (ESPEN)

Nutrient intake from habitual oral diet in patients with severe short bowel syndrome living in the southeastern United States

Contact Info

Product

Resources

About